US Starts Study on Allergic Reaction Risk in Modern, Pfizer Vaccine

The US National Institutes of Health on Wednesday began a mid-stage study to determine the risk of allergy to the COVID-19 vaccine created by Modern Inc. and Pfizer Inc.

Several allergic reactions have occurred, including severe episodes of what is known as anaphylaxis in the US following the vaccinations of Pfizer / Bioentech and Modern Shots.

In January, the US Center for Disease Control and Prevention stated that allergic reactions were occurring at a rate of 11.1 per 1 lakh vaccinations.

Funded by the National Institute of Allergy and Infectious Diseases, the study will enroll 3,400 adults between the ages of 18 and 69, with approximately 60% of participants having a history of severe allergic reactions to food, insect stings, or immunotherapy.

The test aims to reach a proportion of participants who have a systemic allergic reaction within 90 minutes after injection.

The agency expects the data to be reported later this summer.

(This story is not edited by NDTV staff and auto-generated from a syndicated feed.)